Sein métastatique RH+ ESTROTIMP Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (ESTROTIMP) Paris, Saint-Cloud
Sein métastatique HER2+ BO25430 AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD·SPONSORED TRASTUZUMAB EMTANSINE STUDY. Saint-Cloud FLORENCE LEREBOURS
VADS BGB-HNSCC-201 A Randomized, Phase 2, Open-Label, Multi-Arm;Study of Tislelizumab in Combination With;Investigational Agents as First-Line Treatment in;Patients With Recurrent or Metastatic Head and Neck;Squamous Cell Carcinoma. Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ CT7001_003 (SUMIT ELA) A Phase 1b/2 Open-label Study of Samuraciclib in Combination with Elacestrant in;Participants with Metastatic or Locally Advanced Hormone Receptor-positive and Human;Epidermal Growth Factor Receptor 2-negative Breast Cancer. Saint-Cloud FRANCOIS-CLEMENT BIDARD
Sein métastatique triple négatif TOPOLOGY A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer. Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
VADS 219885 219885 GALAXIES H&N-202 A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck Paris CHRISTOPHE LE TOURNEAU